Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Stock analysts at Wedbush lowered their FY2023 earnings per share (EPS) estimates for Eiger Biopharmaceuticals in a research note issued to investors on Monday, August 12th. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will post earnings per share of $0.61 for the year, down from their prior estimate of $0.62. Wedbush has a “Outperform” rating and a $35.00 price target on the stock.

A number of other equities analysts also recently weighed in on EIGR. Zacks Investment Research raised Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Tuesday. ValuEngine raised Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. KeyCorp began coverage on Eiger Biopharmaceuticals in a research report on Wednesday, June 26th. They set an “overweight” rating and a $10.72 price target for the company. Citigroup began coverage on Eiger Biopharmaceuticals in a research report on Wednesday, June 26th. They set a “buy” rating and a $22.00 price target for the company. Finally, LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $28.00 price target on shares of Eiger Biopharmaceuticals in a research report on Monday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $28.34.

NASDAQ:EIGR opened at $9.77 on Wednesday. Eiger Biopharmaceuticals has a twelve month low of $8.40 and a twelve month high of $15.33. The company has a quick ratio of 8.16, a current ratio of 8.16 and a debt-to-equity ratio of 0.62. The business has a 50 day moving average price of $10.71 and a two-hundred day moving average price of $11.96. The company has a market cap of $240.47 million, a P/E ratio of -2.56 and a beta of 1.01.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02).

Several institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in Eiger Biopharmaceuticals in the second quarter valued at about $3,168,000. Cubist Systematic Strategies LLC acquired a new stake in Eiger Biopharmaceuticals in the second quarter valued at about $179,000. Cormorant Asset Management LP acquired a new stake in Eiger Biopharmaceuticals in the second quarter valued at about $12,190,000. Algert Global LLC boosted its stake in Eiger Biopharmaceuticals by 63.2% in the second quarter. Algert Global LLC now owns 28,770 shares of the biotechnology company’s stock valued at $305,000 after buying an additional 11,136 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Eiger Biopharmaceuticals by 39.0% in the second quarter. Vanguard Group Inc. now owns 1,070,914 shares of the biotechnology company’s stock valued at $11,352,000 after buying an additional 300,279 shares in the last quarter. Institutional investors own 80.68% of the company’s stock.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Recommended Story: What does it mean to hold a stock in street name?

Earnings History and Estimates for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.